Candida albicans dimorphism as a therapeutic target

Ilse D Jacobsen; Duncan Wilson; Betty Wächtler; Sascha Brunke; Julian R Naglik; Bernhard Hube

doi:10.1586/eri.11.152

Candida albicans dimorphism as a therapeutic target

Ilse D Jacobsen, Duncan Wilson, Betty Wächtler, Sascha Brunke, Julian R Naglik, Bernhard Hube

Medical Sciences

Research output: Contribution to journal › Article › peer-review

280 Citations (Scopus)

Abstract

The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus Candida albicans. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of C. albicans dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.

Original language	English
Pages (from-to)	85-93
Number of pages	9
Journal	Expert Review of Anti-infective Therapy
Volume	10
Issue number	1
DOIs	https://doi.org/10.1586/eri.11.152
Publication status	Published - Jan 2012

Keywords

Candida albicans
candidiasis
gene expression regulation, fungal
humans
hyphae
virulence
virulence factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/eri.11.152

Cite this

@article{c0b80d65a99a4767bbb56c2f6f28dd32,

title = "Candida albicans dimorphism as a therapeutic target",

abstract = "The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus Candida albicans. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of C. albicans dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.",

keywords = "Candida albicans, candidiasis, gene expression regulation, fungal, humans, hyphae, virulence, virulence factors",

author = "Jacobsen, {Ilse D} and Duncan Wilson and Betty W{\"a}chtler and Sascha Brunke and Naglik, {Julian R} and Bernhard Hube",

year = "2012",

month = jan,

doi = "10.1586/eri.11.152",

language = "English",

volume = "10",

pages = "85--93",

journal = "Expert Review of Anti-infective Therapy",

issn = "1744-8336",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - Candida albicans dimorphism as a therapeutic target

AU - Jacobsen, Ilse D

AU - Wilson, Duncan

AU - Wächtler, Betty

AU - Brunke, Sascha

AU - Naglik, Julian R

AU - Hube, Bernhard

PY - 2012/1

Y1 - 2012/1

N2 - The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus Candida albicans. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of C. albicans dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.

AB - The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus Candida albicans. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of C. albicans dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.

KW - Candida albicans

KW - candidiasis

KW - gene expression regulation, fungal

KW - humans

KW - hyphae

KW - virulence

KW - virulence factors

U2 - 10.1586/eri.11.152

DO - 10.1586/eri.11.152

M3 - Article

C2 - 22149617

SN - 1744-8336

VL - 10

SP - 85

EP - 93

JO - Expert Review of Anti-infective Therapy

JF - Expert Review of Anti-infective Therapy

IS - 1

ER -

Candida albicans dimorphism as a therapeutic target

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this